Continued growth in the UK for Aerogen
The UK and Ireland combined currently makes up about 10% of Galway-based Aerogen’s business. CEO John Power believes the business will continue to grow in the market.
“Brexit won’t noticeably affect medtech growth generally, and I am not overly concerned,” he says.
“One thing that may possibly be missed by Irish companies will be the power base of the UK in terms of a lobby group within Europe.”
Historically the UK and Ireland have always been well aligned in terms of a common sense approach regarding medtech regulation. But Power suspects that Brexit could mean that legislation could become largely driven by France and Germany in the future.
“Both of these countries have strong medtech industry bases and want to protect their own companies,” he says. “But it is not an issue of real concern for us or other medtech companies which will continue to do well in the UK and mainland Europe. For us, it’s a possible challenge that can be overcome.”